Plenary Speakers

Prof. Varinder Aggarwal

University of Bristol, United Kingdom

Prof. Varinder K. Aggarwal studied chemistry at Cambridge University and received his Ph.D. in 1986 under the guidance of Dr. Stuart Warren. After postdoctoral studies (1986-1988) under Prof. Gilbert Stork, Columbia University, he returned to the UK as a Lecturer at Bath University. In 1991 he moved to Sheffield University, where he was promoted to Professor in 1997. In 2000, he moved to Bristol University where he holds the Chair in Synthetic Chemistry. He was elected Fellow of the Royal Society in 2012.

Varinder Aggarwal is a renowned organic chemist who has developed new chemical methods to assemble complex, biologically important molecules. His research includes new catalytic asymmetric methods, developing new classes of reagents for iterative synthesis, and applications of these methods in the synthesis of complex molecules. Early in his career, he showed how to convert the stoichiometric sulfur ylide epoxidation methodology into a catalytic and asymmetric process, and provided a set of rules that govern both diastereoselectivity and enantioselectivity in this important reaction. He later discovered new asymmetric reactions between sulfur ylides/lithiated carbamates and organoboranes/boronic esters which lead to homologated organoboron products in high enantioselectivity including tertiary boronic esters, reactions that could be used iteratively. This work has been particularly impactful, enabling complex molecules to be assembled in a few steps and with very high stereocontrol. Apart from chemistry, his interests include running, cycling, table tennis, yoga, cinema and theatre.

Prof. Fernando Albericio

University of KwaZulu-Natal, South Africa

Prof. Fernando Albericio is a Research Professor at the University of KwaZulu-Natal (South Africa) and Emeritus Professor of Organic Chemistry at the University of Barcelona (Spain) with 50 years of experience in peptide chemistry. His major research interests cover practically all aspects of peptide synthetic methodology as well as the synthesis of peptides and small molecules with therapeutic activities (cancer and infectious diseases). Lastly, he was working on greening the solid-phase peptide synthesis processes. He has published more than 1000 scientific articles, filed more than 60 patents, and graduated more than 80 Ph.D. students. He was recently awarded the 2025 Chemistry Today Lifetime Achievement Award (Teknoscience, Italy), the 2024 Rudinger Award (European Peptide Society), the 2024 Meienhofer Award (Boulder Peptide Foundation), the 2024 Lifetime Achievement Award (European Peptide Synthesis Conference), the 2022 Gold Medal [South Africa Chemistry Institute (SACI)],.and the 2019 Goodman Award (American Peptide Society).

Prof. Dr. Hans-Günther Schmalz

University of Cologne, Germany

Prof. Dr. Hans-Günther Schmalz obtained his PhD in 1985 from Goethe University, Frankfurt, and was subsequently followed by a Postdoc at Princeton University in the USA. Before taking up a position at the University of Cologne in 1999, he served as a Professor of Organic Chemistry at the Technical University Berlin and as a Junior Research Group Leader in the Department of Chemistry at Goethe University, Frankfurt. His research mainly focuses on the development of methods and strategies for the stereoselective synthesis of biologically relevant molecules. In this context, they are exploring, among other things, new possibilities to exploit transition-metal organic chemistry, both in a stoichiometric and in a catalytic manner. Current projects in the group cover a rather broad spectrum of organic chemistry (multistep synthesis of natural products and analogues, enantioselective catalysis, bio-organometallic chemistry, supramolecular chemistry, and chemical biology). Natural products continue to be a major source of inspiration and challenge in his research. He has received numerous awards, including the Albertus Magnus Teaching Award from the University of Cologne and a Teaching Champion from the Technical University Berlin.

Prof. Steven Ballet

Vrije Universiteit Brussel, Belgium

Prof. Steven Ballet completed his PhD (Topic: Constrained aminobenzazepinones for application in peptidomimetics; promotor: Prof. Dirk Tourwé) at the Vrije Universiteit Brussel (VUB, Brussels, Belgium) in 2007. Directly following his PhD training, Dr. Ballet went for a first postdoctoral stay in Australia at the University of Adelaide with Professor Andrew Abell. During this stay, he applied ring-closing and cross-metathesis reactions on amino acid and peptide substrates. As such, dimeric but also ring-closed peptide scaffolds could be obtained. More specifically, RCM was used to stabilize (‘staple’) the helical conformation of alpha and beta peptides. As a second postdoctoral training, Prof. Ballet went to the Institut de Recherches Cliniques de Montréal (IRCM, Montreal, Canada) for specialized training in the opioid peptide field. Together with Prof. Peter W. Schiller, he designed bifunctional opioid ligands with dual MOR/DOR agonist profiles and hybrid opioid/non-opioid multitarget ligands. Since 2010, Prof. Ballet is appointed as a faculty member at his alma mater, where he pursues his efforts in the peptide and peptidomimetic field. Other research topics involve injectable peptide hydrogels for sustained release of bioactive peptides, the synthesis of turn/helix/loop mimetics, and transition metal-catalysed derivatization of peptides in aqueous media. He is the author of over 150 papers, 6 patents and several book chapters.

Prof. Dr. Svetlana B. Tsogoeva

Friedrich-Alexander University of Erlangen-Nürnberg, Germany

Prof. Dr. Svetlana B. Tsogoeva graduated with Distinction in 1995 from St. Petersburg State University, where she completed her doctoral thesis in 1998 on the “Synthesis of Modified Analogues of Steroid Estrogens” supported by Procter & Gamble. Then, she moved to Johann Wolfgang Goethe University, Frankfurt am Main, Germany, for postdoctoral research. In July 2000 she joined the Degussa AG Fine Chemicals Division as a research scientist. In January 2002 she was appointed the first junior professor in Germany at the Georg-August-University of Göttingen. Since February 2007, she has been a Professor of Organic Chemistry at the Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Germany. She has published over 150 papers in international peer-reviewed journals and is among the top 2% of most cited researchers worldwide (Stanford Lists 2021-2024). Her awards and distinctions include a Thieme Chemistry Journal Award (2007), an Otto-Röhm Research Award (2012), Research Grant Awards from the Wilhelm Sander-Stiftung (2015, 2020) and the Volkswagen Foundation (2022, 2025). Her research spans topics from catalysis to medicinal chemistry. She is an Editorial/Advisory Board Member for ACS Med. Chem. Lett, Scientific Reports, ChemPhysChem, Tetrahedron Chem, and a Senior Editor of ACS Central Science.

Professoren FAU Department Chemie Broschüre Einweihung Chemikum Friedrich-Alexander-Universität Erlangen Nürnberg Februar 2018
Nicholas Turner

Prof. Nicholas J. Turner

University of Manchester, United Kingdom

Nicholas Turner is Professor of Chemical Biology, former Director of the Centre of Excellence in Biocatalysis (CoEBio3) and co-Director of SYNBIOCHEM. His research interests span biocatalysis, directed evolution of enzymes and synthetic biology. He has published >450 papers/patents with an h-index of 94 and ca. 30,000 citations. He is a member of several Scientific Advisory Boards and consults widely. He has received many awards for his research achievements and held an ERC Advanced Grant (2017-2023). In May 2020 he was elected a Fellow of the Royal Society (FRS) and in 2021 he became a Member of Academia Europea (MAE). The Turner group (www.turner-biocatalysis.com/) is at the forefront of research aimed at creating new enzymes for application as biocatalysts for chemical synthesis. We employ both protein engineering and directed evolution methods in order to develop biocatalysts with tailored properties such as high stereoselectivity, improved activity and enhanced stability. These biocatalysts have been applied to the synthesis of a range of target molecules especially pharmaceuticals.

Dr. Alexander Makarov

Thermo Fisher Scientific, Germany

Dr. Alexander Makarov obtained his PhD from the Moscow Engineering Physics institute in 1992. In 1996 he embarked on pioneering work on the Orbitrap mass analyzer at HD Technologies Ltd, a small company based in Manchester, UK. After its acquisition by Thermo Electron in 2000, Alexander spearheaded development of the Orbitrap analyzer from first prototypes to the commercial launch of the LTQ Orbitrap instrument in 2005. Under his guidance, the Orbitrap technology expanded to encompass five major families of commercial instruments. He also provided scientific leadership of the Astral analyzer development and technologies for high-mass analysis. His work is reflected in more than 15000 instruments installed worldwide, 150 journal articles, 200 issued US patents, and over 500 patents issued worldwide. In 2020 he was elected a Fellow of the Royal Society (FRS) in the UK. His awards include the Award for Distinguished Contribution in Mass Spectrometry from ASMS, the Aston medal by BMSS and the Thomson medal from IMSF. Presently, he is Director of Research at the Life Science Mass Spectrometry Business Unit of Thermo Fisher Scientific in Bremen, Germany and a Fellow of the Royal Society in the UK.
Alexander Makarov p